Search results for "Bone seeking therapeutic radionuclides"

showing 1 items of 1 documents

Biodistribution and post-therapy dosimetric analysis of [177Lu]Lu-DOTAZOL in patients with osteoblastic metastases: first results

2019

Abstract Background Preclinical biodistribution and dosimetric analysis of [177Lu]Lu-DOTAZOL suggest the bisphosphonate zoledronate as a promising new radiopharmaceutical for therapy of bone metastases. We evaluated biodistribution and normal organ absorbed doses resulting from therapeutic doses of [177Lu]Lu-DOTAZOL in patients with metastatic skeletal disease. Method Four patients with metastatic skeletal disease (age range, 64–83 years) secondary to metastatic castration-resistant prostate carcinoma or bronchial carcinoma were treated with a mean dose of 5968 ± 64 MBq (161.3 mCi) of [177Lu]Lu-DOTAZOL. Biodistribution was assessed with serial planar whole body scintigraphy at 20 min and 3,…

lcsh:Medical physics. Medical radiology. Nuclear medicine[177Lu]Lu-DOTAZOLBiodistributionKidneyUrinary bladderbusiness.industrymedicine.medical_treatmentlcsh:R895-920Organ absorbed dosesBone metastasisBisphosphonatemedicine.diseaseProstate carcinomamedicine.anatomical_structureAbsorbed doseRadionuclide therapymedicineRadiology Nuclear Medicine and imagingBone marrowBronchial carcinomabusinessNuclear medicineBone seeking therapeutic radionuclidesOriginal ResearchEJNMMI Research
researchProduct